Abacavir/lamivudine/zidovudine
 | |
| Combination of | |
|---|---|
| Abacavir | Nucleotide analogue reverse transcriptase inhibitor |
| Lamivudine | Nucleoside analogue reverse transcriptase inhibitor |
| Zidovudine | Nucleoside analogue reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Trizivir |
| AHFS/Drugs.com | FDA Professional Drug Information |
| MedlinePlus | a687007 |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider | |
| NIAID ChemDB | |
  (what is this?) (verify) | |
Abacavir/lamivudine/zidovudine, sold under the trade name Trizivir, is a medication for HIV infection.[1] It is a fixed dose combination of three reverse transcriptase inhibitors patented by GlaxoSmithKline and marketed by a joint venture with Pfizer, ViiV Healthcare:[2]
- abacavir (ABC)
- lamivudine (3TC)
- zidovudine (AZT or ZDV)
It is indicated in the treatment of AIDS/HIV.[3] For this purpose, the combination is very useful in pregnant women to decrease the risk of mother-to-child transmission.[4]
The combination of drugs helps to reduce HIV's resistance (through mutation) to the drugs individually. Of the three, AZT and ABC have passed out of United States patent protection.
In December 2013, Lupin Limited launched a generic version of Trizivir.[5][6] As of 2015 the cost for a typical month of medication in the United States is more than 200 USD.[7]
See also
References
- ^ Opravil, Milos; Hirschel, Bernard; Lazzarin, Adriano; Furrer, Hansjakob; Chave, Jean‐Philippe; Yerly, Sabine; Bisset, Leslie R.; Fischer, Marek; Vernazza, Pietro; Bernasconi, Enos; Battegay, Manuel; Ledergerber, Bruno; Günthard, Huldrych; Howe, Colin; Weber, Rainer; Perrin, Luc (May 2002). "A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection". The Journal of Infectious Diseases. 185 (9): 1251–1260. doi:10.1086/340312.
- ^ InPharm.com: GlaxoSmithKline-Pfizer launch HIV joint venture Archived January 4, 2012, at the Wayback Machine
- ^ Drugs.com: Trizivir
- ^ Horvath, Tara; Madi, Banyana C; Iuppa, Irene M; Kennedy, Gail E; Rutherford, George W; Read, Jennifer S.; Horvath, Tara (2009). "Interventions for preventing late postnatal mother-to-child transmission of HIV" (1): CD006734. doi:10.1002/14651858.CD006734.pub2. PMID 19160297.
{{cite journal}}: Cite journal requires|journal=(help) - ^ Monthly Prescribing Reference (MPR)
- ^ Lupin Pharma
- ^ Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 60. ISBN 9781284057560.
| Subsidiaries |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Predecessors, acquisitions | |||||||||
| Products |
| ||||||||
| People |
| ||||||||
| Litigation | |||||||||
| Other | |||||||||
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |